Joseph P. Lyssikatos's most recent trade in Enliven Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $29.0 . Disclosure was reported to the exchange on Feb. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 29.04 per share. | 06 Feb 2026 | 5,000 | 740,188 | - | 29.0 | 145,219 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 26.90 per share. | 20 Jan 2026 | 14,509 | 745,188 | - | 26.9 | 390,285 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 26.37 per share. | 20 Jan 2026 | 5,491 | 759,697 | - | 26.4 | 144,814 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 29.13 per share. | 08 Jan 2026 | 50,000 | 765,188 | - | 29.1 | 1,456,715 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 24.90 per share. | 08 Jan 2026 | 41,198 | 815,188 | - | 24.9 | 1,025,863 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 24.92 per share. | 08 Jan 2026 | 33,802 | 856,386 | - | 24.9 | 842,474 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 08 Jan 2026 | 7,500 | 890,188 | - | 20.1 | 150,962 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 16.84 per share. | 19 Dec 2025 | 5,000 | 897,688 | - | 16.8 | 84,206 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.30 per share. | 19 Nov 2025 | 12,008 | 903,180 | - | 22.3 | 267,794 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 23.09 per share. | 19 Nov 2025 | 492 | 902,688 | - | 23.1 | 11,361 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.08 per share. | 20 Oct 2025 | 12,500 | 915,188 | - | 22.1 | 276,025 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.25 per share. | 26 Sep 2025 | 4,000 | 927,688 | - | 20.3 | 81,005 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 23 Sep 2025 | 1,500 | 931,688 | - | 20.0 | 30,045 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 19.11 per share. | 19 Sep 2025 | 4,870 | 935,318 | - | 19.1 | 93,063 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.02 per share. | 19 Sep 2025 | 2,130 | 933,188 | - | 20.0 | 42,634 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 19 Aug 2025 | 7,500 | 940,188 | - | 20.0 | 150,099 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 19.62 per share. | 19 Aug 2025 | 5,000 | 947,688 | - | 19.6 | 98,118 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 21 Jul 2025 | 11,924 | 953,264 | - | 22.3 | 265,458 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.90 per share. | 21 Jul 2025 | 576 | 952,688 | - | 22.9 | 13,188 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 21.40 per share. | 20 Jun 2025 | 12,500 | 965,188 | - | 21.4 | 267,458 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 03 Jun 2025 | 7,500 | 977,688 | - | 20.0 | 150,220 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 16.31 per share. | 19 May 2025 | 5,000 | 985,188 | - | 16.3 | 81,534 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 01 May 2025 | 5,030 | 992,658 | - | 20.1 | 100,966 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 01 May 2025 | 2,470 | 990,188 | - | 20.0 | 49,424 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 16.03 per share. | 21 Apr 2025 | 4,670 | 998,018 | - | 16.0 | 74,848 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 16.72 per share. | 21 Apr 2025 | 330 | 997,688 | - | 16.7 | 5,518 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 20.61 per share. | 19 Mar 2025 | 12,500 | 1,002,688 | - | 20.6 | 257,575 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 171,000 | 171,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Oct 2024 | 847 | 1,015,188 | - | 30.0 | 25,413 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 28.12 per share. | 08 Oct 2024 | 34,289 | 1,019,624 | - | 28.1 | 964,203 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 27.96 per share. | 08 Oct 2024 | 13,167 | 1,054,013 | - | 28.0 | 368,173 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 28.52 per share. | 08 Oct 2024 | 3,589 | 1,016,035 | - | 28.5 | 102,358 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 28.51 per share. | 08 Oct 2024 | 100 | 1,053,913 | - | 28.5 | 2,851 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 04 Oct 2024 | 7,522 | 1,069,887 | - | 27.5 | 206,937 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 27.61 per share. | 04 Oct 2024 | 2,707 | 1,067,180 | - | 27.6 | 74,727 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 27.54 per share. | 01 Oct 2024 | 527 | 1,077,409 | - | 27.5 | 14,512 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.48 per share. | 29 Aug 2024 | 11,950 | 1,077,986 | - | 22.5 | 268,687 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 23.08 per share. | 29 Aug 2024 | 50 | 1,077,936 | - | 23.1 | 1,154 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 27.56 per share. | 31 Jul 2024 | 3,099 | 1,089,936 | - | 27.6 | 85,399 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 26.69 per share. | 29 Jul 2024 | 11,797 | 1,093,238 | - | 26.7 | 314,809 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 27.43 per share. | 29 Jul 2024 | 203 | 1,093,035 | - | 27.4 | 5,569 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.89 per share. | 01 Jul 2024 | 12,000 | 1,105,035 | - | 22.9 | 274,736 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 29 May 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 12,000 | 206,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 21.56 per share. | 29 May 2024 | 9,877 | 2,123 | - | 21.6 | 212,988 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 22.52 per share. | 29 May 2024 | 2,123 | 0 | - | 22.5 | 47,813 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 29 Apr 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 12,000 | 218,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 17.86 per share. | 29 Apr 2024 | 10,987 | 1,013 | - | 17.9 | 196,265 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 29 Apr 2024 | 1,013 | 0 | - | 18.5 | 18,723 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2024 | 30,000 | 230,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 11 Apr 2024 | 30,000 | 0 | - | 25.0 | 751,332 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 11 Apr 2024 | 30,000 | 30,000 | - | 1.1 | 33,600 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 01 Apr 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 12,000 | 260,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 18.80 per share. | 01 Apr 2024 | 9,577 | 71 | - | 18.8 | 180,084 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 17.72 per share. | 01 Apr 2024 | 2,352 | 9,648 | - | 17.7 | 41,687 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 19.35 per share. | 01 Apr 2024 | 71 | 0 | - | 19.4 | 1,374 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 29 Feb 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 12,000 | 272,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 16.30 per share. | 29 Feb 2024 | 10,195 | 1,805 | - | 16.3 | 166,152 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 17.09 per share. | 29 Feb 2024 | 1,805 | 0 | - | 17.1 | 30,854 | Common Stock |
| Enliven Therapeutics Inc | Joseph Lyssikatos P. | Director, CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 185,000 | 185,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | P. Joseph Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 15.85 per share. | 29 Jan 2024 | 12,000 | 0 | - | 15.9 | 190,256 | Common Stock |
| Enliven Therapeutics Inc | P. Joseph Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 12,000 | 284,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | P. Joseph Lyssikatos | Director, CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 29 Jan 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 29 Dec 2023 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 12,000 | 296,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | P. Joseph Lyssikatos | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.13 per share. | 29 Dec 2023 | 9,151 | 2,849 | - | 14.1 | 129,268 | Common Stock |
| Enliven Therapeutics Inc | Lyssikatos P. Joseph | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.78 per share. | 29 Dec 2023 | 2,849 | 0 | - | 14.8 | 42,113 | Common Stock |
| Enliven Therapeutics Inc | P. Lyssikatos Joseph | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.07 per share. | 21 Dec 2023 | 6,546 | 0 | - | 13.1 | 85,530 | Common Stock |
| Enliven Therapeutics Inc | P. Lyssikatos Joseph | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 21 Dec 2023 | 6,546 | 6,546 | - | 1.1 | 7,332 | Common Stock |
| Enliven Therapeutics Inc | Lyssikatos Joseph P. | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 6,546 | 308,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Lyssikatos Joseph P. | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 21 Dec 2023 | 20 | 0 | - | 13 | 260 | Common Stock |
| Enliven Therapeutics Inc | Lyssikatos Joseph P. | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 20 | 315,096 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph Lyssikatos P. | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.10 per share. | 21 Dec 2023 | 20 | 20 | - | 1.1 | 22 | Common Stock |
| Enliven Therapeutics Inc | Joseph Lyssikatos P. | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 8,688 | 315,116 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | P. Joseph Lyssikatos | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 19 Dec 2023 | 8,688 | 8,688 | - | 1.1 | 9,731 | Common Stock |
| Enliven Therapeutics Inc | Lyssikatos Joseph P. | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.01 per share. | 19 Dec 2023 | 8,688 | 0 | - | 13.0 | 113,046 | Common Stock |
| Enliven Therapeutics Inc | Lyssikatos P. Joseph | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 19 Dec 2023 | 200 | 200 | - | 1.1 | 224 | Common Stock |
| Enliven Therapeutics Inc | Lyssikatos Joseph P. | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 200 | 323,804 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 19 Dec 2023 | 200 | 0 | - | 13 | 2,600 | Common Stock |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 206,000 | 206,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,117,035 | 1,117,035 | - | - | Common Stock | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 344,550 | 344,550 | - | - | Employee Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Joseph P. Lyssikatos | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 88,531 | 88,531 | - | - | Employee Stock Option (right to buy) |